What question did this study set out to answer?

To evaluate the real-world effectiveness and safety of Risankizumab in Crohn’s disease among Swiss patients.

January 23, 2026

P1135Risankizumab Real World Experience in Switzerland: Report on 130 Patients with Crohn’s Disease from 3 IBD centers

Key Points

To evaluate the real-world effectiveness and safety of Risankizumab in Crohn’s disease among Swiss patients.
Conducted a retrospective chart review across three IBD centers in Switzerland.
Included 130 patients with Crohn's disease receiving Risankizumab treatment.
Assessed patient outcomes based on physician global assessments.
85% of patients showed complete or partial response to Risankizumab.
Most patients initially failed other biologic therapies: 52% on Ustekinumab, 28% anti-TNFs, and 16% Vedolizumab.
Over 90% of patients remained on therapy at follow-up (average 14 months) with no new safety concerns.

Abstract

Abstract Background Risankizumab (Skyrizi®), an IL-23 inhibitor, has demonstrated efficacy in inducing and maintaining remission in Crohn’s disease (CD) 1,2. Methods We conducted a retrospective chart review of CD patients who across three IBD centers: Intesto Bern, Fribourg (also GETAID Center), and Bulle, to report the largest real-world Swiss experience since its Swissmedic approval in September 2023. Results From February 2024 to October 2025, 130 CD (51% female) received at least one dose of Risankizumab. Most patients (85%) failed biologic agents. As last treatment, they mostly failed or were intolerant to Ustekinumab (52%), anti-TNFs (28%) and Vedolizumab (16%). Complete or partial response (based on physician global assessment) was observed in 85% of the CD patients. Risankizumab was administrated in most case (70%) according to the standard regimen, 2% of the patients received a subcutaneous induction and in case of non-response, the strategies were: extended induction (10%) or back to IV treatment (18%). Finally, over 90% of the CD patients remain on therapy at the end of follow-up (mean duration 14 mo), with no new safety signals reported. Conclusion This largest Swiss real-world cohort supports risankizumab as an effective and well-tolerated treatment for patients with refractory Crohn’s disease. In practice, treatment failure with ustekinumab was the most common prior sequence. Re-introducing intravenous administration proved to be the most effective strategy for managing loss of response in selected patients. References: 1. D’Haens G, Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 May 28;399(10340):2015-2030. 2. Bourgonje AR, Ungaro RC, Mehandru S, Colombel JF. Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease. Gastroenterology. 2025 Jan;168(1):29-52.e3. Conflict of interest: Dr. Juillerat, Pascal: Speaker and advisor Fees: AbbVie, Amgen, Aspen Pharmacare, Bristol Myers Squibb, CLS Vifor Pharma, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Johnson & Johnson, Merck Sharp &amp Dohme, Pfizer, Pierre Fabre, Sandoz, Takeda, Tillotts Pharma AG, UCB Pharma. Rossier, Laura: No conflict of interest Ruetsch, Roseline: No conflict of interest Hakiza, Landry: No conflict of interest Weber, Nico: No conflict of interest Nyffeler, Samuel: No conflict of interest Margot, Christelle: No conflict of interest Jasawant, Anne-Sophie: No conflict of interest Bott, Sarah Mirjam: No conflict of interest Anghilina, Camelia: No conflict of interest Tutuian, Georgiana: No conflict of interest Staudenmann, Dominic: No conflict of interest Frei, Cyrille: No conflict of interest Matter, Christoph Bernhard: AbbVie, Takeda, Johnson and Johnson. Seibold, Frank Werner: AbbVie, Eli Lilly, Johnson & Johnson, Sandoz, Takeda,

Bookmark

Cite This Study

Juillerat et al. (Thu,) studied this question.

synapsesocial.com/papers/69730f34c8125b09b0d1f133 https://doi.org/https://doi.org/10.1093/ecco-jcc/jjaf231.1316

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark